Physician profile
Michael Boja
NPI 1811254980
$7,049.32
in general payments reported to CMS, 2019-2025
34 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $631 · 2021: $1,049 · 2022: $1,002 · 2023: $1,364 · 2024: $1,064 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936 · Education: $34.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,935.81 |
| Education | $34.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,159.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $886.29 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $677.07 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $622.00 | 2019-2025 | |
| Lilly USA, LLC | $589.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $428.89 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $328.79 | 2021-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $316.25 | 2021-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $255.18 | 2022-2024 | Seglentis, Livalo, Zoryve |
| Ani Pharmaceuticals, INC. | $225.17 | 2024-2025 | Purified Cortrophin Gel, Valsartan |
| Horizon Therapeutics Plc | $211.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.29 | 2023-2025 | |
| Exact Sciences Corporation | $124.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $110.62 | 2023-2025 | Spravato |
| Pfizer INC. | $105.81 | 2020-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $93.18 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $91.40 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $86.89 | 2023-2025 | Edarbi, Horizant, Edarbi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.97 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $76.66 | 2020-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $70.40 | 2019-2022 | |
| Corcept Therapeutics | $58.31 | 2025 | Korlym |
| Boston Scientific Corporation | $46.46 | 2020-2021 | |
| Dexcom, INC. | $31.86 | 2021 | |
| Medtronic, INC. | $30.32 | 2023 | Inpen Smart Insulin Delivery System |
| Phadia US INC. | $29.46 | 2021-2023 | Immunocap |
| Hikma Pharmaceuticals USA | $27.72 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.73 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.30 | 2024 | Gvoke Hypopen |
| Insulet Corporation | $15.96 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $15.47 | 2025 | Voquezna |
| Sun Pharmaceutical Industries INC. | $13.79 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.17 | 2021 | |
| Abbott Laboratories | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.